Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Applied Biosystems, and Asuragen, a provider of pharmacogenomic services, have announced that they are collaborating with the Critical Path Institute's Predictive Safety Testing Consortium to develop a predictive gene signature panel that will allow pharmaceutical companies to quickly and easily screen potential therapeutics for toxic effects in preclinical samples.
Subscribe to our email newsletter
As part of the collaboration, Critical Path Institute (C-Path), Applied Biosystems, and Asuragen will partner to develop a panel of assays with gene targets determined to be associated with carcinogenicity in laboratory rats, a common model organism for pharmaceutical testing.
The collaborators will also use the Applied Biosystems assays to determine and differentiate effects that are genotoxic from non-genotoxic modes of action to assist in risk assessment. The new biomarker panel will be based on Applied Biosystems’s TaqMan gene signature array and real-time polymerase chain reaction technology.
William Mattes, director of predictive safety testing consortium at C-Path, said: “We expect this collaboration will facilitate broader utility of genomic biomarkers of toxicity across the industry in order to enable the early prediction and mechanistic understanding of potential carcinogens in preclinical research.”